Recently, this possibility was substantiated by a report on symptom-reducing effects of topical anti-sense therapy directed towards CCR3 in asthma [17], although that particular study did not discriminate between an effect on CCR3 and an effect mediated through the common β-chain of the IL-3, IL-5, and GM-CSF receptors. The gene discussed is IL5; the disease is asthma.